Clinical trial
Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer
NCT00319254 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00319254 |
|---|---|
| Title | Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer |
| Official title | Phase II Study Of SKI-606 In Subjects With Advanced Or Metastatic Breast Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | SKI-606 (Bosutinib) |
| Enrollment | 75 |
| Start date | May 1, 2006 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | Apr 27, 2006 |
| Last update posted | Jan 31, 2013 |
| Countries | Australia, France, Hong Kong, Malta, Poland, Russia, Ukraine, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: